Akari Therapeutics, PLC (AKTX)
| Market Cap | 68.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.46M |
| Shares Out | 51.91M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,457 |
| Open | 1.38 |
| Previous Close | 1.40 |
| Day's Range | 1.31 - 1.41 |
| 52-Week Range | 1.29 - 4.21 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+281.7%) |
| Earnings Date | n/a |
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pem...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AKTX stock is "Strong Buy" and the 12-month stock price forecast is 5.00.
News
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercialization New manufacturing process ...
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan a...
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lun...
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia Data suggest potential therapeutic role for nomacopan in exacerbations i...
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
NEW YORK and LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 Inter...
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...
Akari Therapeutics Announces Private Placement
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan a...
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
NEW YORK and LONDON, June 29, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted orphan...
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at...
NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
NEW YORK and LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous...
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
FDA investigational new drug application (IND) now open
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of...
Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma Study of porcine model of blast ...
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
Akari Therapeutics Plc (NASDAQ: AKTX) announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more th...
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat R...
NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and ...
NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...